Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer

Elizabeth G. Grubbs, Zeinab Abdel-Wahab, Douglas Tyler, Scott K. Pruitt

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Real-time quantitative polymerase chain reaction (qPCR) may prove to be a sensitive technique by which to evaluate potential tumor markers in pancreatic cancer. Methods: The prostate stem cell antigen (PSCA) gene was identified as a marker highly expressed in pancreatic adenocarcinoma and not normal pancreas. RNA from pancreatic and nonpancreatic cancer cell lines as well as tissue and blood from pancreatic cancer and control patients was reverse-transcribed and PSCA quantified by qPCR. Results: Individual operator experience affects the results of qPCR, with significantly different copy numbers at experiment numbers 5, 15, and 40. Five of six pancreatic cell lines had PSCA/actin ratios 10-fold greater than nonpancreatic cancer lines. Mean PSCA expression in pancreatic tumor tissue was significantly higher (P < 0.05, Student's t-test) than in the tissue of benign pancreatic processes. The close correlation of PSCA/actin copy number with number of tumor cells in the blood was demonstrated by regression analysis (r = 0.768, P = 0.0001). PSCA copy number was significantly higher in the blood of patients with metastatic pancreatic cancer than in that of normal patients (P < 0.05, Student's t-test). Conclusions: Such trends suggest that PSCA may prove to be a valuable pancreatic cancer tumor marker. More generally, the technique of qPCR is shown to provide a sensitive method of evaluating markers in cancer patients.

Original languageEnglish (US)
Pages (from-to)1645-1654
Number of pages10
JournalAnnals of Surgical Oncology
Volume13
Issue number12
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Tumor Biomarkers
Pancreatic Neoplasms
Prostate
Stem Cells
Antigens
Polymerase Chain Reaction
Actins
Neoplasms
Students
Cell Line
Real-Time Polymerase Chain Reaction
Pancreas
Blood Cells
Adenocarcinoma
Cell Count
Regression Analysis
RNA
Genes

Keywords

  • Pancreatic adenocarcinoma
  • Prostate stem cell antigen
  • Quantitative PCR
  • Tumor marker

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. / Grubbs, Elizabeth G.; Abdel-Wahab, Zeinab; Tyler, Douglas; Pruitt, Scott K.

In: Annals of Surgical Oncology, Vol. 13, No. 12, 12.2006, p. 1645-1654.

Research output: Contribution to journalArticle

@article{a373be82380f4dc8a788109402eb9caa,
title = "Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer",
abstract = "Background: Real-time quantitative polymerase chain reaction (qPCR) may prove to be a sensitive technique by which to evaluate potential tumor markers in pancreatic cancer. Methods: The prostate stem cell antigen (PSCA) gene was identified as a marker highly expressed in pancreatic adenocarcinoma and not normal pancreas. RNA from pancreatic and nonpancreatic cancer cell lines as well as tissue and blood from pancreatic cancer and control patients was reverse-transcribed and PSCA quantified by qPCR. Results: Individual operator experience affects the results of qPCR, with significantly different copy numbers at experiment numbers 5, 15, and 40. Five of six pancreatic cell lines had PSCA/actin ratios 10-fold greater than nonpancreatic cancer lines. Mean PSCA expression in pancreatic tumor tissue was significantly higher (P < 0.05, Student's t-test) than in the tissue of benign pancreatic processes. The close correlation of PSCA/actin copy number with number of tumor cells in the blood was demonstrated by regression analysis (r = 0.768, P = 0.0001). PSCA copy number was significantly higher in the blood of patients with metastatic pancreatic cancer than in that of normal patients (P < 0.05, Student's t-test). Conclusions: Such trends suggest that PSCA may prove to be a valuable pancreatic cancer tumor marker. More generally, the technique of qPCR is shown to provide a sensitive method of evaluating markers in cancer patients.",
keywords = "Pancreatic adenocarcinoma, Prostate stem cell antigen, Quantitative PCR, Tumor marker",
author = "Grubbs, {Elizabeth G.} and Zeinab Abdel-Wahab and Douglas Tyler and Pruitt, {Scott K.}",
year = "2006",
month = "12",
doi = "10.1245/s10434-006-9029-5",
language = "English (US)",
volume = "13",
pages = "1645--1654",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer

AU - Grubbs, Elizabeth G.

AU - Abdel-Wahab, Zeinab

AU - Tyler, Douglas

AU - Pruitt, Scott K.

PY - 2006/12

Y1 - 2006/12

N2 - Background: Real-time quantitative polymerase chain reaction (qPCR) may prove to be a sensitive technique by which to evaluate potential tumor markers in pancreatic cancer. Methods: The prostate stem cell antigen (PSCA) gene was identified as a marker highly expressed in pancreatic adenocarcinoma and not normal pancreas. RNA from pancreatic and nonpancreatic cancer cell lines as well as tissue and blood from pancreatic cancer and control patients was reverse-transcribed and PSCA quantified by qPCR. Results: Individual operator experience affects the results of qPCR, with significantly different copy numbers at experiment numbers 5, 15, and 40. Five of six pancreatic cell lines had PSCA/actin ratios 10-fold greater than nonpancreatic cancer lines. Mean PSCA expression in pancreatic tumor tissue was significantly higher (P < 0.05, Student's t-test) than in the tissue of benign pancreatic processes. The close correlation of PSCA/actin copy number with number of tumor cells in the blood was demonstrated by regression analysis (r = 0.768, P = 0.0001). PSCA copy number was significantly higher in the blood of patients with metastatic pancreatic cancer than in that of normal patients (P < 0.05, Student's t-test). Conclusions: Such trends suggest that PSCA may prove to be a valuable pancreatic cancer tumor marker. More generally, the technique of qPCR is shown to provide a sensitive method of evaluating markers in cancer patients.

AB - Background: Real-time quantitative polymerase chain reaction (qPCR) may prove to be a sensitive technique by which to evaluate potential tumor markers in pancreatic cancer. Methods: The prostate stem cell antigen (PSCA) gene was identified as a marker highly expressed in pancreatic adenocarcinoma and not normal pancreas. RNA from pancreatic and nonpancreatic cancer cell lines as well as tissue and blood from pancreatic cancer and control patients was reverse-transcribed and PSCA quantified by qPCR. Results: Individual operator experience affects the results of qPCR, with significantly different copy numbers at experiment numbers 5, 15, and 40. Five of six pancreatic cell lines had PSCA/actin ratios 10-fold greater than nonpancreatic cancer lines. Mean PSCA expression in pancreatic tumor tissue was significantly higher (P < 0.05, Student's t-test) than in the tissue of benign pancreatic processes. The close correlation of PSCA/actin copy number with number of tumor cells in the blood was demonstrated by regression analysis (r = 0.768, P = 0.0001). PSCA copy number was significantly higher in the blood of patients with metastatic pancreatic cancer than in that of normal patients (P < 0.05, Student's t-test). Conclusions: Such trends suggest that PSCA may prove to be a valuable pancreatic cancer tumor marker. More generally, the technique of qPCR is shown to provide a sensitive method of evaluating markers in cancer patients.

KW - Pancreatic adenocarcinoma

KW - Prostate stem cell antigen

KW - Quantitative PCR

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=33845677702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845677702&partnerID=8YFLogxK

U2 - 10.1245/s10434-006-9029-5

DO - 10.1245/s10434-006-9029-5

M3 - Article

VL - 13

SP - 1645

EP - 1654

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -